(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard
|
|
- Adele Riley
- 5 years ago
- Views:
Transcription
1 Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1
2 Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer- Gasse 3, A-1140 Vienna DHE "ratiopharm" 2,5 mg - Kapseln 2.5 mg prolonged-release ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer- Gasse 3, A-1140 Vienna DHE "ratiopharm" 5 mg - Kapseln 5 mg prolonged-release Amdipharm Ltd. 3, Burlington Road,, Dihydergot 2,5 mg - Tabletten 2.5 mg tablet WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Ergovasan 2 mg/ml - Tropfen 2 mg/ml oral drops, solution WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Ergovasan 2,5 mg retard - Kapseln 2.5 mg prolonged-release 2
3 Belgium Belgium Finland WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Burlington Road, 3 Laboratoires Belges PHARMACOBEL SA Avenue de Scheut Brussels Belgium PIERRE FABRE MEDICAMENT 45, place Abel Gance Boulogne Billancourt PIERRE FABRE MEDICAMENT 45, place Abel Gance Boulogne Billancourt Ergovasan 5 mg retard - Kapseln 5 mg prolonged-release Dihydergot Forte 2,5 mg Tablet Dystonal 2,5 mg Tablet ORSTANORM 2.5 mg tablet IKARAN L.P. 5 mg, comprimé à libération prolongée IKARAN, solution buvable en gouttes 5 mg prolonged-release tablet 0.20 g /100 ml oral drops, solution 3
4 UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes UCB PHARMA 420 Avenue Estienne d'orves Défense Ouest Colombes Alfa Wasserman Pharma SAS 67 rue Anatole, Levallois Perret AMDIPHARM 3, Burlington Road DUBLIN 4 IRELAND AMDIPHARM 3, Burlington Road DUBLIN 4 SEGLOR 2 mg/ml, solution buvable en gouttes 2 mg/ml oral solution SEGLOR 5 mg, gélule 5 mg hard capsule SEGLOR LYOC 5 mg, lyophilisat oral 5 mg oral lyophilisate TAMIK, capsule 3 mg soft capsule DIHYDROERGOTAMINE AMDIPHARM 2 mg/ml, solution buvable DIHYDROERGOTAMINE AMDIPHARM 3 mg, comprimé 2 mg/ml oral solution 3 mg tablet 4
5 Temple Chamcers, 3 Burlington Road IRL- Dihydergot plus Lösung zum Einnehmen 2 mg/ 1 ml 10 mg/ 1 ml Solution Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str. 173 D Ingelheim Effortil plus 0.2 g/ 100 ml 1 g/ 100 ml Solution CT Arzneimittel GmbH Lengeder Str. 42 a D Berlin CT Arzneimittel GmbH Lengeder Str. 42 a D Berlin DET MS Tropflösung 2 mg/ 1 ml Solution Ergotam-CT 2,5mg Retardkapseln Ergotam-CT 5,0mg Retardkapseln 2.5 mg Prolonged-released capsule 5 mg Prolonged-released capsule UCB Pharma GmbH Alfred-Nobel-Str. 10 D Monheim Verla-Pharm Arzneimittel GmbH & Co.KG Hauptstr. 98 D Tutzing Agit depot sanol 5 mg Prolonged-released Verladyn 2 mg/ 1 ml solution 5
6 Greece Luxembourg Amdipharm Ltd.,, Teofarma srl Via Fratelli Cervi, Valle Salimbene Pavia Teofarma srl Via Fratelli Cervi, Valle Salimbene Pavia Acarpia - Servicos Farmaceuticos LDA Rua dos Murcas, 88 Funchal Madeira - Portugal Pierre Fabre Médicaments 45, PLACE ABEL GANCE F BOULOGNE CEDEX Dihydergot 2.5 mg tablet DIIDERGOT 2 mg/ml oral solution DIIDERGOT 3 mg tablet SEGLOR 5 mg modifiedreleasecapsule, hard Ikaran 0.20 g /100 ml oral solution Luxembourg Pierre Fabre Médicaments 45, PLACE ABEL GANCE F BOULOGNE CEDEX Ikaran L.P. 5 mg tablets 6
7 Poland Farmaceutyczna Spółdzielnia Pracy FILOFARM ul. Pułaskiego Bydgoszcz Poland Poland Farmaceutyczna Spółdzielnia Pracy FILOFARM ul. Pułaskiego Bydgoszcz Poland Portugal Laboratórios Azevedos - Indústria Farmacêutica, S.A. PRT Edifícios Azevedos - Estrada Nacional 117-2, Alfragide Amadora Portugal Dihydroergotaminum Filofarm 2 mg/g oral solution DHE - tar 1 mg tablet Seglor Retard 5 mg Prolonged-release Slovenia Spain LEK farmacevtska družba d.d., Verovskova 57, SI-1526 Ljubljana, Slovenia Ditamin 2,5 mg tablete 2,5 mg tablet DIHYDERGOT COMPRIMIDOS 1 mg tablet 7
8 Sweden Sweden Orstanorm 2,5 mg Tablets Orstanorm 5 mg Tablets 8
(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma
More informationMember State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder
More information(Invented) Name Strength Pharmaceutical form. Ergomed - Tropfen (1:1:1) ERSILAN 1mg/ml Oral drops, solution oral use mg/19.
Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states 1 Member State (in EEA) Marketing
More information(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria
More informationOrlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATIONS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Belgium Belgium Belgium Belgium
More informationProduct name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml
Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of, marketing authorisation s in the Member States 1 Bulgaria Estonia Zentiva k.s. 130 U kabelovn Prague 10237 Czech
More information(Invented) Name Strength Pharmaceutical form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria
More informationMember State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
More information(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium
More informationAnnex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection
07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 SEGLOR 5 mg, hard capsule B/30 (CIP code: 321 899-8) SEGLOR LYOC 5 mg, oral lyophilisate B/30 (CIP code:
More informationPlease note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 TAMIK Ge 3 mg, soft capsule B/60 (CIP code: 322 714-1) Applicant: IPRAD dihydroergotamine mesylate ATC
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 IKARAN LP 5 mg, tablets B/30 (CIP: 339 287-4) IKARAN Ge 2 mg/ml, oral solution in drops Vial of 50 ml
More informationAmoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of applicant/marketing authorisation holder in the member states 1/10 Member State EU/EEA
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal
More informationINN Product name Strength Pharmaceutical form
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationMember State Marketing Authorisation Holder Invented Name Strength Pharmaceutical Route of administration
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing
More information4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection
ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration. BufloMed 'S.Med' 300 mg Filmtabletten
Annex I List of the invented names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing
More informationSortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria
More informationPackage leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir
Package leaflet: Information for the patient Valotix 500 mg Film-Coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationMember State Marketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES CHMP/309507/2007 1/6 EMEA
More informationQuality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationMarketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. DRYNOL 20 MG TABLETS bilastine
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DRYNOL 20 MG TABLETS bilastine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you only.
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationPUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 15 June 1999 EMEA/18046/99 PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationPackage leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate
Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER
ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER January 2007 1/5 Member State Applicant or Marketing Authorisation
More informationTadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan
More informationPackage leaflet: Information for the patient. Amlode 5 mg Tablets Amlode 10 mg Tablets. amlodipine
Package leaflet: Information for the patient Amlode 5 mg Tablets Amlode 10 mg Tablets amlodipine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
ANNEX I ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 4 A. MANUFACTURING AUTHORISATION HOLDERS Manufacturers
More informationMember State Marketing Authorisation Holder Product Name Strength Pharmaceutical Form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPackage leaflet: Information for the user. Zirtek 1 mg/ml oral solution. Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPACKAGE LEAFLET For medicinal products available on prescription
PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet
More information(Invented) name Strength Pharmaceutical Form Route of administration. Losec 10mg Kapseln 10 mg capsule, hard Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Marketing Authorisation
More informationFree Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationProduct Name Strength Pharmaceutical Form. Valproat-Ratiopharm Chrono 300 mg. Valproat-Ratiopharm Chrono 500 mg
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES (EU/EEA) 1 Member State (EU/EEA) Czech
More informationPACKAGE LEAFLET For medicinal products available on prescription
PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Tetmodis 25 mg tablets {Tetrabenazine} Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationPackage leaflet: Information for the patient
Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride Read all of this leaflet carefully
More informationProduct name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State (in EEA) Marketing authorisation
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPackage leaflet: Information for the patient. Telmisartan Rowex 40 mg Tablets Telmisartan Rowex 80 mg Tablets. telmisartan
Package leaflet: Information for the patient Telmisartan Rowex 20 mg Tablets Telmisartan Rowex 40 mg Tablets Telmisartan Rowex 80 mg Tablets telmisartan Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationGood Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014
Good Laboratory Practice EU-Serbia screening meeting Brussels, 19 June 2014 Table of contents 1. Background information on the principles of GLP 2. EU legal basis for GLP 3. Role of Member States 4. Role
More informationPackage leaflet: Information for the patient. CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab
Package leaflet: Information for the patient CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION,
ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATE 1 SERTINDOLE
More informationPackage leaflet: information for the user. Ondansetron 4 mg Film-Coated Tablets Ondansetron 8 mg Film-Coated Tablets
Package leaflet: information for the user Ondansetron 4 mg Film-Coated Tablets Ondansetron 8 mg Film-Coated Tablets Ondansetron (as hydrochloride dihydrate) Read all of this leaflet carefully before you
More informationThis document is a preview generated by EVS
TECHNICAL REPORT RAPPORT TECHNIQUE TECHNISCHER BERICHT CEN/TR 17223 March 2018 ICS 03.100.70; 11.040.01 English version Guidance on the relationship between EN ISO 13485: 2016 (Medical devices - Quality
More informationMember State Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation
More informationMENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa
MENTAL HEALTH CARE OECD HCQI Expert meeting 17 th of May, 2013 Rie Fujisawa Mental health indicators Any hospital readmissions for patients with schizophrenia Same hospital readmissions for patients with
More informationApplicant/MAH (Invented) Name Strength Pharmaceutical Form. Fentanyl STADA Depotpflaster. Fentanyl EG Pleister voor transdermaal gebruik
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS AND MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 1 Member State Marketing
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 Karvezide 150/12.5 mg tablets Irbesartan/hydrochlorothiazide PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR TABLETS Your doctor has prescribed this medicine for you.
More informationPackage leaflet: Information for the user. Zirtek Allergy 1 mg/ml oral solution. Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek Allergy 1 mg/ml oral solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important
More informationANNEX III LABELLING AND PACKAGE LEAFLET ANNEX
ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX B. PACKAGE LEAFLET 2 NAME OF THE MEDICINAL PRODUCT OLANSEK 2.5 mg TABLETS (OLANZAPINE) GENERAL ADVICE Please read this information carefully before you start
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Vatan 40 mg Film-Coated Tablets Vatan 80 mg Film-Coated Tablets Vatan 160 mg Film-Coated Tablets Vatan 320 mg Film-Coated Tablets valsartan Read all of this
More informationTiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET
Tiorfix Tiorfast 100 mg PACKAGE LEAFLET 1 Tiorfix Tiorfast 100 mg Package leaflet: Information for the user 100 mg hard capsules Racecadotril Read all of this leaflet carefully before you start taking
More informationPackage leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride
Package leaflet: Information for the patient Avodart 0.5 mg soft capsules dutasteride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationProduct name Strength Pharmaceutical form. Myolastan 50 mg - Filmtabletten. Tetrazepam-MIP 50 mg Tabletten
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation holders in the Member States 1 Member State (in EEA) Marketing
More informationPackage leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol
Package leaflet: Information for the patient Paracetamol Read all of this leaflet carefully before you are given this medicine because it contains important information for you. - Keep this leaflet. You
More informationArticle 31 of Directive 2001/83/EC resulting from pharmacovigilance data
29 November 2012 EMA/764460/2012 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation s in the member states for
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Clozapin Regiomedica 50 mg/ml Suspension zum Einnehmen Clozamedica 50 mg/ml Suspension zum Einnehmen
More informationLescol 20 mg - Kapseln 20 mg Capsule, hard Oral use. Lescol 40 mg - Kapseln 40 mg Capsule, hard Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Marketing Authorisation
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Calcium Sandoz 500 mg, effervescent tablets Calcium Sandoz 1000 mg, effervescent tablets Calcium Read all of this leaflet carefully because it contains important
More informationPackage leaflet: Information for the patient. Tamnexyl XL 400micrograms Prolonged-release Tablets. Tamsulosin hydrochloride
Package leaflet: Information for the patient Tamnexyl XL 400micrograms Prolonged-release Tablets Tamsulosin hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: Information for the patient
Xyzal 5 mg/ml oral drops, solution Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride
More informationInvented name Strength. 125mg/5ml. 250mg/5ml
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States Member State (EU/EEA) Marketing Authorisation
More informationPackage leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate
Package leaflet: Information for the patient Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate Read all of this leaflet carefully before you are given this medicine because
More informationPackage leaflet: Information for the User Clarityn 10 mg tablets Loratadine
Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always
More informationLegal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS
Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationAmidex 1 mg film-coated tablets
Package leaflet: Information for the user Amidex 1 mg film-coated tablets Anastrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationPackage leaflet: Information for the user
Sandoz B.V. Page 1/8 Package leaflet: Information for the user Pioglitazon Lek 15 mg, tabletten Pioglitazon Lek 30 mg, tabletten Pioglitazon Lek 45 mg, tabletten Pioglitazone Read all of this leaflet carefully
More informationPatient Information Leaflet
1.1.1 1.3.1.3 Patient Information Leaflet Package leaflet: Information for the patient Prapexin 0.088 mg Tablets Prapexin 0.18 mg Tablets Prapexin 0.7 mg Tablets Pramipexole Read all of this leaflet carefully
More information